Survey study population
| Demographics | Number of patients (n=164) |
| Age, mean years (SD) | 40 (13) |
| Women (cisgender), no (%) | 87 (53) |
| Disease type, no (%) | |
| Ulcerative colitis | 62 (38) |
| Crohn’s disease | 75 (46) |
| Fistulising Crohn’s disease | 27 (16) |
| Disease duration, median (IQR) | 10 (5–18) |
| Biologic therapy, no (%) | |
| Infliximab | 111 (68) |
| Adalimumab | 19 (12) |
| Vedolizumab | 21 (13) |
| Golimumab | 8 (5) |
| Certolizumab | 1 (1) |
| Ustekinumab | 4 (2) |
| Self-reported disease activity, no (%) | |
| No symptoms | 100 (61) |
| Mild | 29 (18) |
| Moderate | 28 (17) |
| Severe | 7 (4) |